Yohana Antunes, B.Sc.
Lab manager, ISMMS
Graduated in Biomedical Sciences by the Federal University of Parana, I currently works as a Senior Research Associate in the Mulder lab. I am involved in projects that study trained immunity in the treatment of cancer and myocardial infarction. In addition, I am also involved in research on the use of nanoparticles for treatment and imaging of atherosclerotic diseases. My fields of expertise include microscopy, molecular biology and cellular biology.
Bram Teunissen, Ph.D.
Instructor, ISMMS
I have a strong background in organic and supramolecular chemistry and am currently working as a postdoctoral researcher in the Mulder lab. Here, my research focuses on drug derivatization and the synthesis, development and radiolabeling of nanotherapeutics.
Mandy van Leent, M.D.
Postdoctoral fellow, ISMMS
My research concentrates on the application of nanobiologics in atherosclerosis and ischemic heart disease. The main focus is evaluating efficacy and targeting potential of different nanobiologics by various immunological assays and molecular imaging.
Anu Meerwaldt, M.Sc.
PhD student, UMCU
I am focusing on evaluating immunomodulatory nanotherapies in ischemic stroke. With advanced molecular imaging techniques we aim to further elucidate the complex poststroke immune activation and the effects of targeted immunomodulatory therapy in experimental stroke models.
Max Senders, M.D.
PhD student, AMC
My research focuses on imaging macrophage dynamics in the context of cardiovascular disease. Molecular PET imaging allows targeting specific process in the atherosclerotic plaque, while nanotechnology-faciliated MR imaging can be deployed to study immunological processes longitudinally. Eventually these imaging protocols may facilitate (nano)drug development, improved identification of high risk patients and evaluation of novel therapeutics.
Ewelina Kluza, Ph.D.
Postdoctoral fellow, AMC
My current projects are focused on the structural and functional integrity of atherosclerotic endothelium, and on nanomedicine-based strategies for treatment of atherosclerosis. In my research, I employ advanced microscopy methods including the super-resolution fluorescence and correlative light-electron microscopy.
Bram Priem, M.D.
PhD student, AMC/VUmc
My research focuses on improving cancer immunotherapy with the use of nanotechnology. With rationally designed nanoparticles we harness te power of the innate immune system to promote an effective and immediate immune response against cancer. This technology can be used as a stand-alone therapy or to enhance currently used immunotherapies like checkpoint inhibitors.
Thijs Beldman, M.Sc.
PhD student, AMC
My research is aimed at the development and evaluation of cannabinoid incorporated nanoparticles. By using reconstituted HDL nanoparticles we aim to target the endocannabinoid system in myeloid cells to inhibit the immune response and improve the outcome of inflammation driven diseases.
Roderick Oosterwijk
MSc student, TU/e
Developing HDL nanobiologics that specifically target and polarize macrophages in atherosclerotic lesions.
Alexandros Sofias, M.Sc.
PhD student, NTNU
My main goal is to improve targeted drug delivery for nanomedicines utilised in oncology. For succeding this, I study nanoparticle targeting mechanisms and biodistribution profiles using live imaging techniques.
Jazz Munitz
BSc student, Cornell
I am a current undergraduate at Cornell University, and have been learning and researching in the Mulder lab since my Sophomore year of high school. The focus of my research is on the development of nanotechnology-based immunotherapies for the treatment of cancer, with hopes of being part of the inventive and patient-oriented future of medicine.
Emma Klein, M.Sc.
Research associate, ISMMS
I am interested in novel imaging techniques and their application to medicine. My research focuses on improving drug delivery for the treatment of inflammatory diseases. I recently graduated from Washington University in St. Louis with degrees in Systems and Biomedical Engineering.
